UA83204C2 - Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome - Google Patents

Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome

Info

Publication number
UA83204C2
UA83204C2 UAA200505319A UAA200505319A UA83204C2 UA 83204 C2 UA83204 C2 UA 83204C2 UA A200505319 A UAA200505319 A UA A200505319A UA A200505319 A UAA200505319 A UA A200505319A UA 83204 C2 UA83204 C2 UA 83204C2
Authority
UA
Ukraine
Prior art keywords
treatment
myelodysplastic syndrome
acute leukemia
combination therapy
pharmaceutical combinations
Prior art date
Application number
UAA200505319A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Джей Маршалл Файнгольд
Original Assignee
Уайт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Уайт filed Critical Уайт
Priority to UAA200505319A priority Critical patent/UA83204C2/en
Publication of UA83204C2 publication Critical patent/UA83204C2/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods of treatment and pharmaceutical combinations are provided for the treatment of acute leukemia, such as acute myelogenous leukemia, and myelodysplastic syndrome. The methods of treatment and pharmaceutical combinations employ an anli-CD33 cytotoxic conjugate in combination with at least one compound selected from the group consisting of an anthracycline and a pyrimidine or purine nucleoside analog. Preferred methods of treatment and pharmaceutical combinations employ gemtuzumab ozogamicin, daunorubicin, and cytarabine.
UAA200505319A 2002-11-06 2002-11-06 Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome UA83204C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UAA200505319A UA83204C2 (en) 2002-11-06 2002-11-06 Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UAA200505319A UA83204C2 (en) 2002-11-06 2002-11-06 Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome

Publications (1)

Publication Number Publication Date
UA83204C2 true UA83204C2 (en) 2008-06-25

Family

ID=50721928

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200505319A UA83204C2 (en) 2002-11-06 2002-11-06 Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome

Country Status (1)

Country Link
UA (1) UA83204C2 (en)

Similar Documents

Publication Publication Date Title
NO20052009L (en) Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
HUT72460A (en) Synergetic antiviral nucleoside combination, pharmaceutical preparation containing thereof, method of preparation, and use
BRPI9809791B8 (en) aminoalkyl glucosamine phosphate immuno-effecting compounds and compositions comprising the same
WO2005102359A8 (en) Liposomal formulations of anthracycline agents and cytidine analogs
CO5050297A1 (en) USE OF PEG-IFN-ALFA AND RIBAVIRINE FOR THE TREATMENT OF CHRONIC HEPATITIS C
MX368013B (en) Cancer treatment.
WO2004028475A3 (en) Glycosylceramide analogues
WO2004087713A8 (en) Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
MY133016A (en) Antitumor composition containing a synergistic combination of an anthracycline derivative with a camptothecin derivate
WO2004012662A3 (en) Improved treatment of cancer with glutamine
IL173785A0 (en) Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents
AU2158601A (en) Antiviral agent for use in treatment of cancer
WO2005076888A3 (en) Anti-cancer therapies
CA2401191A1 (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
AUPQ879500A0 (en) Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
HUP0400153A2 (en) Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment
AU2002347747A1 (en) Retinol derivatives, their use in the treatment of cancer and for potentiating the efficacy of other cytotoxic agents
JP2005530735A5 (en)
UA83022C2 (en) Aplidine for the combination therapies of leukemia and lymphoma
HUP0300219A2 (en) Compositions and methods for l-nucleosides, l-nucleotides, and their analogs
WO2005000204A3 (en) Pancreatic cancer treatment
UA83204C2 (en) Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
WO2005079849A3 (en) Compounds for enhanced cancer therapy
HUP0402401A2 (en) Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the treatment of cancer
CA2213099A1 (en) S-(+)-adenosylmethionine and 3'-azido-2',3'-dideoxy-nucleoside complexes as potent inhibitors of hiv-replication